{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T22:08:29Z","timestamp":1774649309858,"version":"3.50.1"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100001458","name":"American Kennel Club Canine Health Foundation","doi-asserted-by":"publisher","award":["01569"],"award-info":[{"award-number":["01569"]}],"id":[{"id":"10.13039\/100001458","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Canine cutaneous T-cell lymphoma (CTCL) is an uncommon disease for which efficacious therapies are lacking. The novel anticancer nucleotide prodrug VDC-1101 (formerly known as GS-9219) has shown efficacy in dogs with multicentric lymphoma. One of the observed adverse effects with this drug was a skin change characterized by hair loss, erythema, and pruritus, implying delivery of VDC-1101 to the skin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis\/Objectives<\/jats:title>\n                    <jats:p>The primary study objective was to identify the objective response rate (ORR) to VDC-1101 in canine CTCL; secondary objectives included characterization of progression-free survival (PFS) and adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Animals<\/jats:title>\n                    <jats:p>Twelve dogs with chemotherapy-na\u00efve or relapsed, histologically and immunohistochemically confirmed CTCL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Dogs received VDC-1101 as a 30-minute IV infusion once every 21 days. Prednisone (1 mg\/kg PO q48h) was administered concurrently.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 11 evaluable patients, responses included 1 complete response (CR), 4 partial responses (PR), 2 stable disease (SD), and 4 progressive disease for an ORR of 45% and biologic response rate (CR\/PR\/SD) of 64%. The median PFS was 37.5 days (26 to &amp;gt;399 days), which includes 1 durable and ongoing CR (&amp;gt;1 year). Gastrointestinal and hematologic AEs were mild; no dogs developed grade 3 or 4 AEs. Three dogs developed dermatopathies and 1 of these dogs was removed from the study as a result of this AE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions and Clinical Importance<\/jats:title>\n                    <jats:p>VDC-1101 has activity against canine CTCL and could provide another treatment option in a disease process with a poor prognosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jvim.12429","type":"journal-article","created":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T13:48:48Z","timestamp":1412171328000},"page":"1569-1574","source":"Crossref","is-referenced-by-count":32,"title":["Phase II Evaluation of VDC-1101 in Canine Cutaneous T-Cell Lymphoma"],"prefix":"10.1093","volume":"28","author":[{"given":"M.A.","family":"Morges","sequence":"first","affiliation":[{"name":"Flint Animal Cancer Center, Colorado State University , Fort Collins, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.H.","family":"Burton","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine, University of California , Davis, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.F.","family":"Saba","sequence":"additional","affiliation":[{"name":"College of Veterinary Medicine, The University of Georgia , Athens, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.M.","family":"Vail","sequence":"additional","affiliation":[{"name":"School of Veterinary Medicine, University of Wisconsin-Madison , Madison, WI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.E.","family":"Burgess","sequence":"additional","affiliation":[{"name":"Foster Hospital for Small Animals, Cummings School of Veterinary Medicine, Tufts University , North Grafton, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.H.","family":"Thamm","sequence":"additional","affiliation":[{"name":"Flint Animal Cancer Center, Colorado State University , Fort Collins, CO"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,9,1]]},"reference":[{"key":"2026020304403690400_jvim12429-bib-0001","first-page":"608","volume-title":"Small Animal Clinical Oncology","author":"Vail","year":"2013","edition":"5th ed"},{"key":"2026020304403690400_jvim12429-bib-0002","first-page":"22","volume-title":"Skin Tumors of the Dog and Cat","author":"Goldschmidt","year":"1992"},{"key":"2026020304403690400_jvim12429-bib-0003","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-3164.2007.00582.x","article-title":"Investigation on the association between atopic dermatitis and the development of mycosis fungoides in dogs: A retrospective case-control study","volume":"18","author":"Santora","year":"2007","journal-title":"Vet Dermatol"},{"key":"2026020304403690400_jvim12429-bib-0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1476-5829.2008.00176.x","article-title":"Canine cutaneous epitheliotropic T-cell lymphoma: A review","volume":"7","author":"Fontaine","year":"2009","journal-title":"Vet Compar Oncol"},{"key":"2026020304403690400_jvim12429-bib-0005","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-3164.2009.00793.x","article-title":"Canine cutaneous epitheliotropic T-cell lymphoma: A review of 30 cases","volume":"21","author":"Fontaine","year":"2010","journal-title":"Vet Dermatol"},{"key":"2026020304403690400_jvim12429-bib-0006","first-page":"641","volume-title":"Cancer in the Dog and Cat-Medical and Surgical Management","author":"Morrison","year":"2001","edition":"2nd ed"},{"key":"2026020304403690400_jvim12429-bib-0007","first-page":"1330","volume-title":"Muller and Kirk's Small Animal Dermatology","author":"Scott","year":"2001","edition":"6th ed"},{"key":"2026020304403690400_jvim12429-bib-0008","first-page":"566","article-title":"Mycosis fungoides in a dog: Demonstration of T-cell specificity and response to radiotherapy","volume":"26","author":"DeBoer","year":"1990","journal-title":"J Am An Hosp Assoc"},{"key":"2026020304403690400_jvim12429-bib-0009","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0304-3835(92)90016-O","article-title":"Linoleate produces remission in canine mycosis fungoides","volume":"64","author":"Iwamoto","year":"1992","journal-title":"Cancer Lett"},{"key":"2026020304403690400_jvim12429-bib-0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.2460\/javma.1993.202.03.387","article-title":"Use of isotretinoin and etretinate for the treatment of benign cutaneous neoplasia and cutaneous lymphoma in dogs","volume":"202","author":"White","year":"1993","journal-title":"J Am Vet Med Assoc"},{"key":"2026020304403690400_jvim12429-bib-0011","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1111\/j.1939-1676.2006.tb00756.x","article-title":"Response of canine cutaneous epitheliotropic lymphoma to lomustine (CCNU): A retrospective study of 46 cases (1999\u20132004)","volume":"20","author":"Risbon","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026020304403690400_jvim12429-bib-0012","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1939-1676.2006.tb02833.x","article-title":"CCNU in the treatment of canine epitheliotropic lymphoma","volume":"20","author":"Williams","year":"2006","journal-title":"J Vet Intern Med"},{"key":"2026020304403690400_jvim12429-bib-0013","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-3164.1997.tb00262.x","article-title":"Treatment of cutaneous T-cell lymphoma with dacarbazine in a dog","volume":"8","author":"Lemarie","year":"1997","journal-title":"Vet Dermatol"},{"key":"2026020304403690400_jvim12429-bib-0014","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1158\/1078-0432.CCR-07-2061","article-title":"GS-9219\u2014A novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma","volume":"14","author":"Reiser","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2026020304403690400_jvim12429-bib-0015","doi-asserted-by":"crossref","first-page":"21966","DOI":"10.1074\/jbc.273.34.21966","article-title":"Incorportation and excision of 9-(2-phosphonylmethoxyethyl)guanine (PMEG) by DNA polymerase delta and epsilon in vitro","volume":"273","author":"Kramata","year":"1998","journal-title":"J Biol Chem"},{"key":"2026020304403690400_jvim12429-bib-0016","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/jnci\/82.6.510","article-title":"In vivo antitumor activity of 9-[(2-phosphonylmethoxy)ethyl]-guanine and related phosphonate neucleotide analogues","volume":"82","author":"Rose","year":"1990","journal-title":"J Natl Cancer Inst"},{"key":"2026020304403690400_jvim12429-bib-0017","first-page":"195","article-title":"9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine: A novel prodrug of 9-(2-phosphonylmethoxyethyl)guanine with improved antitumor efficacy and selectivity in choriocarcinoma-bearing rats","volume":"11","author":"Nasesens","year":"1999","journal-title":"Oncol Res"},{"key":"2026020304403690400_jvim12429-bib-0018","first-page":"2057","article-title":"Antitumour activity of N6-substituted PMEDAP derivatives against T-cell lymphoma","volume":"21","author":"Valerianova","year":"2001","journal-title":"Anticancer Res"},{"key":"2026020304403690400_jvim12429-bib-0019","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1158\/1078-0432.CCR-08-3113","article-title":"Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma","volume":"15","author":"Vail","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2026020304403690400_jvim12429-bib-0020","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1740-8261.2009.01612.x","article-title":"Use of 3'-deoxy-3'-[18F]fluorothymidine PET\/CT for evaluating response to cytotoxic chemotherapy in dogs with non-Hodgkin's lymphoma","volume":"50","author":"Lawrence","year":"2009","journal-title":"Vet Radiol Ultrasound"},{"key":"2026020304403690400_jvim12429-bib-0021","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1136\/vr.144.22.611","article-title":"Chronic pulmonary disease in West Highland white terriers","volume":"29","author":"Corcoran","year":"1999","journal-title":"Vet Rec"},{"key":"2026020304403690400_jvim12429-bib-0022","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1939-1676.2011.0694.x","article-title":"Clinical, bronchoscopic, histopathologic, diagnostic imaging, and arterial oxygenation findings in West Highland White Terriers with idiopathic pulmonary fibrosis","volume":"25","author":"Heikkil\u00e4","year":"2011","journal-title":"J Vet Intern Med"},{"key":"2026020304403690400_jvim12429-bib-0023","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1476-5810.2004.0053a.x","article-title":"Veterinary Co-operative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0","volume":"2","author":"Vail","year":"2004","journal-title":"Vet Comp Oncol"}],"container-title":["Journal of Veterinary Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.12429","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvim.12429","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/28\/5\/1569\/66686579\/jvim12429.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jvim\/article-pdf\/28\/5\/1569\/66686579\/jvim12429.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T09:40:59Z","timestamp":1770111659000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jvim\/article\/28\/5\/1569\/8452238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,1]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,9,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jvim.12429","relation":{},"ISSN":["1939-1676"],"issn-type":[{"value":"1939-1676","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,9]]},"published":{"date-parts":[[2014,9,1]]}}}